RxDoctor Payments Data

Franz Murphy

Vascular Surgery · Kearney, NENPI 1194953059

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,045 of the $4,745 with a category attached, or 85.2%. 29 manufacturers reported payments, led by Endologix LLC at 30.7% of the total. That places this record below the midpoint for vascular surgery clinicians in NE, where the typical reported total is $4,193.

$4,745in general payments, 2019–2025

Across 85 payments — averaging $55.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endologix LLC$1K
  • Medtronic$1K
  • Abbott$406
  • Musculoskeletal Transplant Foundation Inc.$266
  • W. L. Gore & Associates, Inc.$258
  • Inari Medical, Inc.$216
  • plus $1K from 23 others

What the payments were for

  • Travel & lodging$70015%
  • Food & beverage$4,04585%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,745 in reported general payments places this provider in the 50th percentile of 35 vascular surgery providers in Nebraska.

See all vascular surgery providers in Nebraska

Medicare billing

Part B allowed, 2024
$262,383
Medicare patients
786
Services billed
1,745

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban69$45,472
Cilostazol24$503
ClopidogrelClopidogrel Bisulfate76$453
Diazepam20$15

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$114$45,47269 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 35 vascular surgery providers in Nebraska.

Other vascular surgery in Kearney

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →